Prognostic significance of mutation type and chromosome fragility in Fanconi anemia
American Journal of Hematology · 2025
DOI: 10.1002/ajh.27520 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift American Journal of Hematology, 2025. Verfasst von María José Ramírez und 59 weiteren Autor:innen. Beteiligte Einrichtung: Joint Research Unit on Genomic Medicine, Universitat Autònoma de Barcelona (UAB)-IR SANT PAU, Barcelona, Spain. Hauptthemen laut MEDLINE: Chromosome Fragility, Fanconi Anemia, Fanconi Anemia Complementation Group A Protein, Fanconi Anemia Complementation Group G Protein. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundació Institut Català de Recerca i Estudis Avançats, Ministerio de Ciencia, Innovación y Universidades, Agència de Gestió d'Ajuts Universitaris i de Recerca.
Abstract (Originalsprache)
Fanconi anemia (FA) is a rare genetic disease characterized by high phenotypic and genotypic heterogeneity, and extreme chromosome fragility. To better understand the natural history of FA, identify genetic risk and prognostic factors, and develop novel therapeutic strategies, the Spanish Registry of Patients with FA collects data on clinical features, chromosome fragility, genetic subtypes, and DNA sequencing with informed consent of participating individuals. In this article, we describe the clinical evolution of 227 patients followed up for up to 30 years, for whom our data indicate a cumulative cancer incidence of 86% by age 50. We found that patients with lower chromosome fragility had a milder malformation spectrum and better outcomes in terms of later‐onset hematologic impairment, less severe bone marrow failure, and lower cancer risk. We also found that outcomes were better for patients with mutations leading to mutant FANCA protein expression (genetic hypomorphism) than for patients lacking this protein. Likewise, prognosis was consistently better for patients with biallelic mutations in FANCD2 (mainly hypomorphic mutations) than for patients with biallelic mutations in FANCA and FANCG , with the lack of the mutant protein in patients with biallelic mutations in FANCG contributing to their poorer outcomes. Our results regarding the clinical impact of chromosome fragility and genetic hypomorphism suggest that mutant FA proteins retain residual activity. This finding should encourage the development of novel therapeutic strategies aimed at partially or fully enhancing mutant FA function, thereby preventing or delaying bone marrow failure and cancer in patients with FA. Clinical Trial Registration number: NCT06490510.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Joint Research Unit on Genomic Medicine, Universitat Autònoma de Barcelona (UAB)-IR SANT PAU, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CIBERER, ISCIII), Madrid, Spain.
- Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
- La Paz Hospital Institute for Health Research (IdiPAZ), La Paz University Hospital; Pediatric Oncohematology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.
- Department of Genetics and Microbiology, Faculty of Biosciences, Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID-Profile: María José Ramírez, Ilaria Persico, Debora Cavero, Miguel López de Heredia, M Luisa Antelo, Marta Baragaño, Cristina Beléndez, María Isabel Buedo, Estela Carrasco, Ines Hernández-Rodríguez, Mónica López, Salvador Payán-Pernía, María A Ramos-Arroyo, Juan Pablo Trujillo-Quintero, José Manuel Vagace, Jaime Verdú-Amorós
Förderung
- Fundació Institut Català de Recerca i Estudis Avançats
- Ministerio de Ciencia, Innovación y Universidades
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- the Instituto de Salud Carlos III (ISCIII) and fondos Next Generation EU
- Instituto de Salud Carlos III
Zitieren
APA
Ramírez, M. J., Pujol, R., Minguillón, J., Bogliolo, M., Persico, I., Cavero, D., de la Cal, A., Río, P., Navarro, S., Casado, J. A., Bailador, A., de la Fuente, A. S., de Heredia, M. L., Almazán, F., Antelo, M. L., Argilés, B., Badell, I., Baragaño, M., Beléndez, C., …, & Verdugo, V. (2025). Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. American Journal of Hematology. https://doi.org/10.1002/ajh.27520
Vancouver
Ramírez MJ, Pujol R, Minguillón J, Bogliolo M, Persico I, Cavero D, et al. Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. American Journal of Hematology. 2025. doi:10.1002/ajh.27520
BibTeX
@article{Ramrez2025,
author = {Ramírez, María José and Pujol, Roser and Minguillón, Jordi and Bogliolo, Massimo and Persico, Ilaria and Cavero, Debora and de la Cal, Aurora and Río, Paula and Navarro, Susana and Casado, José Antonio and Bailador, Almudena and de la Fuente, Antonio Sanchez and de Heredia, Miguel López and Almazán, Francisco and Antelo, M Luisa and Argilés, Bienvenida and Badell, Isabel and Baragaño, Marta and Beléndez, Cristina and Bermúdez, Mar and Bernués, Marta and Buedo, María Isabel and Carrasco, Estela and Català, Albert and Costa, Dolors and Cuesta, Isabel and Fernandez-Delgado, Rafael and Fernández-Teijeiro, Ana and Figuera, Ángela and García, Marta and Gondra, Ainhoa and González, Macarena and Muñiz, Soledad González and Hernández-Rodríguez, Ines and Ibañez, Fátima and Kelleher, Nicholas John and Lendínez, Francisco and López, Mónica and López-Almaraz, Ricardo and Marchante, Inmaculada and Mendoza, Carmen and Nieto, José and Ojeda, Emilio and Payán-Pernía, Salvador and Peláez, Irene and de Soto, Inmaculada Pérez and Portugal, Raquel and Ramos-Arroyo, María A and Regueiro, Alexandra and Rodríguez, Ana and Rosell, Jordi and Saez, Raquel and Sánchez, José and Sánchez, Martha and Senent, MªLeonor and Tapia, María and Trujillo-Quintero, Juan Pablo and Vagace, José Manuel and Verdú-Amorós, Jaime and Verdugo, Victória},
title = {Prognostic significance of mutation type and chromosome fragility in Fanconi anemia},
journal = {American Journal of Hematology},
year = {2025},
doi = {10.1002/ajh.27520}
}
EUVIMED